Aurora Sustainable Lands and Anew Climate combine proven land stewardship and innovative, technology-driven carbon quantification to deliver verifiable climate benefits
Read MoreJaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID
Company completed meeting with FDA October 2, 2025 for advice on advancing its ongoing placebo-controlled trial of crofelemer in support of possible expedited approval pathway for crofelemer for treatment of MVID
Read More
It's the last call for the smart shopping app's holiday promotions, which provide increasing cashback rewards at spending milestones and offer double cashback rewards on select brands through Monday, Dec. 15.
Read MoreFirst strategic investment by Ondas Capital intended to strengthen U.S. and allied defense modernization priorities with combat-proven Ukrainian technologies
Ondas Capital plans to support localization via U.S.-based, NDAA-compliant manufacturing and integrated customer support, training and sustainment
Read More
HIGHLIGHTS
More than 60 historic drillholes digitised to date record >3,000 ppm U₃O₈, confirming the district's strong uranium-vanadium signature.
Mapping of a 700 ppm U₃O₈ cut-off envelope underway, defining multiple coherent mineralised trends.
A distinct northwest target zone (Dakota/Burro Canyon) identified, with historic assays up to 0.45% U₃O₈ and 3.45% V₂O₅.
UAR enters a collaboration with DISA Technologies to undertake bench-scale metallurgical test work and site surveys at no cost to UAR.
Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price
Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors
Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience
Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have access to controlled substances for legitimate medical use.
Today, the evidence shows the opposite: DEA officials laundering cartel money, DEA lawyers defending unconstitutional judicial processes, DEA executives cycling into industry roles they once regulated and DEA policies obstructing legitimate FDA authorized medical research.
Read MoreNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.
Read MoreNE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI PUBLIER, DISTRIBUER OU DIFFUSER, DIRECTEMENT OU INDIRECTEMENT, EN TOTALITÉ OU EN PARTIE, AUX ÉTATS-UNIS OU À DESTINATION DES ÉTATS-UNIS.
Read More
